James Mulshine to Antineoplastic Agents
This is a "connection" page, showing publications James Mulshine has written about Antineoplastic Agents.
Connection Strength
0.620
-
Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. Bioinformatics. 2008 Feb 01; 24(3):389-95.
Score: 0.255
-
Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8.
Score: 0.086
-
A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity. Am J Clin Oncol. 1990 Aug; 13(4):285-9.
Score: 0.078
-
Developing CT image-processing tools to accelerate progress in lung cancer drug development. Oncology (Williston Park). 2006 Nov; 20(12):1606, 1608-10, 1614 passim.
Score: 0.060
-
Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer. 2003 Aug; 41 Suppl 1:S163-74.
Score: 0.048
-
Lung cancer evolution to preinvasive management. Clin Chest Med. 2002 Mar; 23(1):37-48.
Score: 0.043
-
Lung cancer: current therapies and new targeted treatments. Lancet. 2017 01 21; 389(10066):299-311.
Score: 0.030
-
Treatment of non-small-cell lung cancer. J Clin Oncol. 1986 Nov; 4(11):1704-15.
Score: 0.015
-
Second IASLC Workshop on Combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Biological basis of combined therapy. Lung Cancer. 1994 Mar; 10 Suppl 1:S3-5.
Score: 0.006